MEDEZE.BK Medeze Group PCL
- Market cap
- THB 5.98B
- P/E
- 46.7x
- P/B
- 2.03x
- ROE
- 5.1%
- Dividend yield
- 2.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MEDEZE.BK undervalued?
Graham numberMEDEZE.BK trades 105.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medeze Group PCL fundamental analysis
No fundamental analysis for Medeze Group PCL yet.
Medeze Group PCL stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medeze Group PCL
Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in r…
Full company profileMedeze Group PCL financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medeze Group PCL annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 702M | 829M | 744M | 645M |
| Gross Profit | 550M | 648M | 547M | 480M |
| Operating Income | 304M | 364M | 228M | 197M |
| EBITDA | 332M | 413M | 288M | 214M |
| Net Income | 240M | 339M | 196M | 149M |
| EPS | 0.22 | 0.32 | 0.18 | 0.14 |
| Balance Sheet | ||||
| Total Assets | 1.02B | 3.43B | 3.48B | 3.49B |
| Total Liabilities | 444M | 506M | 565M | 542M |
| Shareholders' Equity | 575M | 2.92B | 2.91B | 2.95B |
| Cash & Short-term Investments | 183M | 897M | 1.26B | 1.09B |
| Cash Flow | ||||
| Operating Cash Flow | 348M | 327M | 167M | 215M |
| Capital Expenditure | 51.5M | 294M | 184M | 55.4M |
| Free Cash Flow | 296M | 32.6M | -17.1M | 160M |
| Ratios | ||||
| ROE | 41.7% | 11.6% | 6.7% | 5.1% |
| ROA | 23.5% | 9.9% | 5.6% | 4.3% |
| Net Profit Margin | 34.1% | 40.9% | 26.4% | 23.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Medeze Group PCL dividends
- Dividend yield
- 2.86%
- Forward dividend
- 0.16 THB
- Payout ratio
- 87.0%
- Ex-dividend date
- Apr 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | THB 171M | 0.16 | 87.0% |
| 2024 | THB 333M | 0.31 | 98.4% |
| 2023 | THB 270M | 0.25 | 112.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medeze Group PCL
- Insiders 81.70%
- Institutions 0.00%
- Public & others 18.30%
- Shares outstanding 1.07B
- Free float 247M
Medeze Group PCL company profile
- Company name
- Medeze Group PCL
- Ticker
- MEDEZE.BK
- Exchange
- Thailand Exchange
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Fiscal year end
- December
- Address
- 28/9 Moo 8, Nakhon Pathom, Thailand, 73220
- Phone
- 66 9 1599 9999
- Website
- medezegroup.com
About Medeze Group PCL
Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular activities and medical laboratory tests. Further, the company sells dietary supplements, cosmetics, and dermo cosmetics. Medeze Group Public Company Limited was founded in 2010 and is based in Nakhon Pathom, Thailand.
Medeze Group PCL management
7- Dr. Veerapol KhemarangsanCo-Founder, CEO & Director
- Associate Prof. Rangsun ParnpaiCo-founder
- Dr. Chumrus SakulpaisalCo-founder
- Ms. Phunurai AkkarasacksakunCOO & Director
- Dr. Tanut Kunkanjanawan Ph.D.Chief Laboratory Officer & Director
- Dr. Rachanee O-charoenChief Medical Officer & Director
- Ms. Danita PhithaknetikunChief Business Development Officer & Director